ClinicalTrials.gg
RecruitingNCT07505745MOTS-METUpdated Apr 1, 2026

MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity

A Phase 2 interventional study of MOTS-c (MDP) and Placebo in Prediabetes, Insulin Resistance and Overweight/Obesity, sponsored by Hudson Biotech. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Hudson Biotech · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Prediabetic State with a site in China — 24 open to participants now, 25 under way, 1 of them phase 3. Prediabetic State · China.

Planned enrollment
25th of 44
120 · median 160
Started
2026
with 8 others
Phase 2
4 of 51
2 open now
Primary completion
2027-02
later than 15 of 24 live
Registered
44th of 51
by date

Among the 51 studies in Prediabetic State with a site in China, this one is the 25th largest by planned enrollment of the 44 interventional ones that give a count, is one of 9 that started in 2026, is one of 4 in phase 2, reaches primary completion later than 15 of the 24 other live ones, and was the 44th registered.

Prediabetic State

919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.

Browse Prediabetic State studies →

Open to participants now

24 of the 51 studies in Prediabetic State with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Prediabetic State with a site in China, or all of them as a file.
02

Study summary

This Phase 2a study evaluates whether 12 weeks of treatment with investigational MOTS-c improves insulin sensitivity compared with placebo in adults with prediabetes and overweight/obesity.

Participants are randomized 1:1 to MOTS-c or placebo, receive standardized lifestyle counseling, and are followed for safety through Week 16.

Read the detailed description

Mitochondrial-derived peptides (MDPs) are small peptides encoded by mitochondrial DNA that can act as signaling molecules. MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) has been reported to regulate insulin sensitivity and metabolic homeostasis in preclinical studies, with skeletal muscle identified as a key target tissue and AMPK activation proposed as a downstream mechanism. Based on these findings, this trial is designed to test the hypothesis that MOTS-c can improve insulin sensitivity and cardiometabolic risk markers in humans with early metabolic dysfunction. The study includes a screening period (up to 4 weeks), a 12-week double-blind treatment period, and a 4-week post-treatment safety follow-up. Efficacy is assessed using a 75 g oral glucose tolerance test (OGTT)-derived insulin sensitivity index and standard metabolic endpoints (HbA1c, fasting glucose, lipids, body weight, and waist circumference). Safety assessments include adverse events, vital signs, ECG, and laboratory testing.

03

Conditions studied

  • Prediabetes
  • Insulin Resistance
  • Overweight/Obesity

Keywords

  • MOTS-c
  • mitochondrial-derived peptide
  • MDP
  • insulin sensitivity
  • AMPK
  • prediabetes
  • metabolic syndrome
  • OGTT
  • HbA1c
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 65 years at the time of consent.
  • (BMI) 27.0 to 40.0 kg/m\^2.
  • Prediabetes documented at screening by any of the following: (a) 5.7% to 6.4%; (b) fasting plasma glucose 100 to 125 mg/dL; or (c) 2-hour plasma glucose 140 to 199 mg/dL during a 75 g OGTT.
  • Stable body weight (less than 5% change) for at least 3 months prior to screening.
  • Willingness to maintain stable diet and physical activity patterns during the 12-week treatment period.
  • For participants of : agreement to use highly effective for the study duration and for a protocol-specified period after last dose.
  • Ability to understand and sign .

Exclusion criteria

Exclusion Criteria:

  • Diabetes mellitus (e.g., 6.5% or higher, fasting plasma glucose 126 mg/dL or higher, or 2-hour glucose 200 mg/dL or higher at screening).
  • Use of glucose-lowering medications (including metformin, GLP-1 receptor agonists, SGLT2 inhibitors) within 3 months prior to screening.
  • History of bariatric surgery or planned weight-loss surgery during the study period.
  • cardiovascular disease within 6 months (e.g., myocardial infarction, stroke, unstable angina) or uncontrolled hypertension.
  • Estimated (eGFR) \< 60 mL/min/1.73 m\^2, clinically significant hepatic disease, or /AST > 2.5x at screening.
  • Active requiring treatment (except adequately treated non-melanoma skin cancer).
  • Pregnant, breastfeeding, or planning pregnancy during the study period.
  • Known to peptide therapeutics or any component of the product formulation.
  • Any condition that, in the investigator's judgment, would interfere with study participation or interpretation of results (e.g., inability to comply with study procedures).
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    MOTS-c

    Participants receive investigational MOTS-c plus standardized lifestyle counseling.

    Drug: MOTS-c (MDP) · Other: Route Subcutaneous injection · Other: Regimen

  • Placebo comparator
    Placebo

    Participants receive matching placebo plus standardized lifestyle counseling.

    Drug: Placebo · Other: Route Subcutaneous injection · Other: Regimen

Interventions

  • DrugMOTS-c (MDP)

    Drug: MOTS-c (MDP)

  • DrugPlacebo

    Drug: Placebo

  • OtherRoute Subcutaneous injection

    injection

  • OtherRegimen

    Fixed dose once daily for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change from baseline in OGTT-derived insulin sensitivity (Matsuda Index)

    Time frame: 12 Weeks

  2. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: 16 weeks

Secondary outcomes

  1. Change from baseline in HbA1c.

    Time frame: 12 Weeks

  2. Change from baseline in fasting glucose

    Time frame: 12 weeks

  3. Change from baseline in 2-hour plasma glucose during 75 g OGTT.

    Time frame: 12 weeks

  4. Immunogenicity (anti-drug antibodies, if applicable).

    Time frame: 16 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Feb 2027, 12 months after the start.

Of 27 phase 2 interventional studies under Prediabetic State, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 69. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2026
First posted
Apr 1, 2026
StartActual
Feb 2, 2026
Primary completionEst.
Feb 14, 2027
CompletionEst.
May 17, 2028
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07505745
Lead sponsor
Hudson Biotech
Responsible party
Sponsor
First posted
Apr 1, 2026
Start date
Feb 2, 2026
Primary completion
Feb 14, 2027 (estimated)
Completion
May 17, 2028 (estimated)
Last update
Apr 1, 2026

Study contacts

Seni S Lu, Phd
Contact
Seni-Lu@beijing-biotech.com
+86 13076790030

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion